Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2016

Open Access 01-04-2016 | Original Article

R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy

Authors: Akira Nagahara, Motohide Uemura, Atsunari Kawashima, Takeshi Ujike, Kazutoshi Fujita, Yasushi Miyagawa, Norio Nonomura

Published in: International Journal of Clinical Oncology | Issue 2/2016

Login to get access

Abstract

Background

We investigated the association between the R.E.N.A.L. nephrometry score (RNS) and the postoperative recurrence of localized renal cell carcinoma (RCC).

Methods

We retrospectively analyzed a database comprising 91 patients with non-small localized RCC (pT1b–T2b) treated by radical nephrectomy at our hospital from January 2002 to March 2010. RNS was scored based on imaging findings at diagnosis. The Cox proportional hazards model was used to predict recurrence-free survival (RFS) and to calculate hazard ratio (HR).

Results

The median age at operation was 63 years (range, 30–85 years). Postoperative recurrence occurred in 19 patients (21 %). Median RNS sum was 9 (range, 5–11). High RNS sum (10–12) was significantly associated with RFS (P = 0.0012). Multivariate analysis revealed that high RNS sum [HR, 9.05; 95 % confidence interval (CI), 2.11–63.9; P = 0.0019] were significantly associated with RFS. Regarding each component of RNS, only the L component, which referred to tumor location relative to the polar line, was associated with RFS (HR, 15.0; 95 % CI, 2.68–396; P = 0.0006).

Conclusions

RNS was associated with RFS in cases of non-small localized RCC (pT1b–2b), thus supporting its utility as a prognostic factor.
Literature
1.
Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182:844–853CrossRefPubMed
2.
Ficarra V, Novara G, Secco S et al (2009) Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol 56:786–793CrossRefPubMed
3.
Simmons MN, Ching CB, Samplaski MK et al (2010) Kidney tumor location measurement using the C index method. J Urol 183:1708–1713CrossRefPubMed
4.
Kutikov A, Smaldone MC, Egleston BL et al (2011) Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol 60:241–248CrossRefPubMedPubMedCentral
5.
Wang H-K, Zhu Y, Yao X-D et al (2012) External validation of a nomogram using RENAL nephrometry score to predict high grade renal cell carcinoma. J Urol 187:1555–1560CrossRefPubMed
6.
Satasivam P, Sengupta S, Rajarubendra N et al (2012) Renal lesions with low R.E.N.A.L nephrometry score are associated with more indolent renal cell carcinomas (RCCs) or benign histology: findings in an Australian cohort. BJU Int 109(Suppl):44–47CrossRefPubMed
7.
Mullins JK, Kaouk JH, Bhayani S et al (2012) Tumor complexity predicts malignant disease for small renal masses. J Urol 188:2072–2076CrossRefPubMed
8.
Kopp RP, Mehrazin R, Palazzi KL et al (2014) Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score. BJU Int 114:708–718CrossRefPubMed
9.
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed
10.
Miyake H, Furukawa J, Hinata N et al (2014) Significant impact of R.E.N.A.L. nephrometry score on changes in postoperative renal function early after robot-assisted partial nephrectomy. Int J Clin Oncol 20:586–592CrossRefPubMed
11.
Long J-A, Arnoux V, Fiard G et al (2013) External validation of the RENAL nephrometry score in renal tumours treated by partial nephrectomy. BJU Int 111:233–239CrossRefPubMed
12.
Liu Z-W, Olweny EO, Yin G et al (2013) Prediction of perioperative outcomes following minimally invasive partial nephrectomy: role of the R.E.N.A.L nephrometry score. World J Urol 31:1183–1189CrossRefPubMed
13.
Hayn MH, Schwaab T, Underwood W, Kim HL (2011) RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy. BJU Int 108:876–881PubMed
14.
Rosevear HM, Gellhaus PT, Lightfoot AJ et al (2012) Utility of the RENAL nephrometry scoring system in the real world: predicting surgeon operative preference and complication risk. BJU Int 109:700–705CrossRefPubMed
15.
Altunrende F, Laydner H, Hernandez AV et al (2013) Correlation of the RENAL nephrometry score with warm ischemia time after robotic partial nephrectomy. World J Urol 31:1165–1169CrossRefPubMed
16.
Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (Phila) 97:1663–1671CrossRef
17.
Sorbellini M, Kattan MW, Snyder ME et al (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173:48–51CrossRefPubMed
18.
Muramaki M, Miyake H, Sakai I et al (2011) Age at diagnosis as a powerful predictor for disease recurrence after radical nephrectomy in Japanese patients with pT1 renal cell carcinoma. Int J Urol 18:121–125CrossRefPubMed
19.
Matsumoto R, Abe T, Shinohara N et al (2014) RENAL nephrometry score is a predictive factor for the annual growth rate of renal mass. Int J Urol 21:549–552CrossRefPubMed
20.
Ramsey S, Lamb GW, Aitchison M, McMillan DC (2008) Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 101:959–963CrossRefPubMed
21.
Jeong IG, Yoo CH, Song K et al (2009) Age at diagnosis is an independent predictor of small renal cell carcinoma recurrence-free survival. J Urol 182:445–450CrossRefPubMed
22.
Shvarts O, Seligson D, Lam J et al (2005) P53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173:725–728CrossRefPubMed
23.
Ito K, Yoshii H, Sato A et al (2011) Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol 186:430–435CrossRefPubMed
24.
Fujita N, Okegawa T, Terado Y et al (2014) Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. BMC Res Notes 7:369CrossRefPubMedPubMedCentral
25.
Hongo F, Takaha N, Oishi M et al (2014) CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. Urol Oncol 32:1240–1246CrossRefPubMed
Metadata
Title
R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy
Authors
Akira Nagahara
Motohide Uemura
Atsunari Kawashima
Takeshi Ujike
Kazutoshi Fujita
Yasushi Miyagawa
Norio Nonomura
Publication date
01-04-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0879-3

Other articles of this Issue 2/2016

International Journal of Clinical Oncology 2/2016 Go to the issue

Original Article

A population-based study on the associations between chronic periodontitis and the risk of cancer

Original Article

Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes

Original Article

Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy

Original Article

Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer

Original Article

Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients

Original Article

Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits